Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

6019 - Clinical utility of serum type III collagen in patients with pancreatic carcinoma.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Translational Research

Tumour Site

Pancreatic Adenocarcinoma

Presenters

Inna Chen

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

I. Chen1, N. Willumsen2, C. Dehlendorff3, A. Johansen1, B.V. Vittrup1, M. Krüger1, P. Pfeiffer4, J.K. Bjerregaard4, S.E. Bojesen5, S.E. Nielsen6, N.H. Holländer7, M.K. Yilmaz8, L.S. Rasmussen9, M. Karsdal2, J.S. Johansen1

Author affiliations

  • 1 Department Of Oncology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 2 Biomarkers And Research, Nordic Bioscience A/S, 2730 - Herlev/DK
  • 3 Statistics And Pharmacoepidemiology, Danish Cancer Society Research Center, Copenhagen/DK
  • 4 Experimental Research In Medical Cancer Therapy, Odense University Hospital, 5000 - Odense C/DK
  • 5 Department Of Clinical Biochemistry, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 6 Department Of Oncology, North Zealand University Hospital, 3400 - Hillerød/DK
  • 7 Department Of Oncology, Zealand University Hospital in Næstved, 4180 - Næstved/DK
  • 8 Department Of Oncology, Aalborg University Hospital, Aalborg/DK
  • 9 Oncology, Aalborg University Hospital, 9000 - Aalborg/DK

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 6019

Background

Collagen is highly expressed in pancreatic cancer (PC) stroma. Collagen accumulation compromises penetration of macromolecules into tumor tissues and is associated with poorer outcome and increased tumor invasion. The aim of this biomarker study was to investigate the clinical utility of serum pro-peptide of type III collagen (PRO-C3) in patients (pts) with PC.

Methods

A cohort from the Danish BIOPAC study (ClinicalTrials.gov ID: NCT03311776) including 851 consecutive subjects with histologically confirmed PC, ampullary carcinoma (n = 45), distal biliary tract cancer (n = 32) and benign lesions (n = 88) were enrolled. Serum PRO-C3 was determined by ELISA (Nordic Bioscience, PRO-C3 protocol). The main outcome was survival among pts with PC (male/female: 458/393; age <50 vs. 50-69 vs. ≥70: 41/477/333; ECOG Performance Status (PS) of 0/1/2+: 315/340/110; stage 1 + 2/3/4: 234/142/456; diabetes yes/no: 207/629; smoking yes/no: 508/265; alcohol yes/no: 183/588; body mass index: low/normal/overweight: 62/426/254; Charlson Age-Comorbidity index (CACI) 0/1-2/3+: 34/296/504) in relation to PRO-C3 levels. Serum CA19-9, hyaluronic acid (HA), C-reactive protein (CRP), interleukin-6 (IL-6) and YKL-40 were measured. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by Cox proportional hazards regression.

Results

HA, CRP, IL-6, YKL-40, higher PS and stage were all risk factors for poor outcome in univariate analyses, as was log2-transformed PRO-C3 (HR = 1.15, 95% CI 1.09-1.22, P < 0.001). No statistically significant difference for serum PRO-C3 was observed in multivariate model, while CA19-9, CRP, YKL-40 along with higher PS and stage remained independently significant. PRO-C3 was positively correlated with higher stage (P = 0.012) and was significantly higher in pts with PC compared to subjects with benign lesions (P < 0.001).

Conclusions

Compared with subjects with benign lesions serum PRO-C3 was higher in pts with PC, and increased with greater stage. Higher levels were associated with shorter OS. Serum PRO C3 did not provide independent prognostic value compared to other markers. Further investigations are warranted based on these initial results.

Clinical trial identification

Legal entity responsible for the study

Julia Sidenius Johansen.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.